NCT00055978View on ClinicalTrials.gov

Celecoxib in Preventing Lung Cancer in Former Heavy Smokers

PHASE2CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

March 31, 2008

Study Completion Date

May 31, 2009

Conditions
Lung Cancer
Interventions
DRUG

celecoxib

Given orally. 400mg twice daily for 6 months.

OTHER

placebo

Given orally

Trial Locations (1)

90095-1781

Jonsson Comprehensive Cancer Center at UCLA, Los Angeles

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of California, Los Angeles

OTHER

NCT00055978 - Celecoxib in Preventing Lung Cancer in Former Heavy Smokers | Biotech Hunter | Biotech Hunter